Company: SXTPW
Filing Date: 2025-02-06
Form Type: 424B5
Source: 0001213900-25-010772
Chunk: 53

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-02-06
Form: 424B5
Chunk 53
---
CDC”) as Post-Treatment Lyme Disease Syndrome (“PTLDS”) or simply as Lyme in the patient community.2                                         
 Although there are no published estimates, key opinion leaders have stated that as many as 50% of Lyme/PTLDS patients are believed to          
 be co-infected with Babesia parasites, a diagnosis referred to in the Lyme community as “Chronic Babesiosis.” Prescribers                      
 in the Lyme disease community utilize a number of therapeutic modalities to manage the symptoms of Chronic Babesiosis, including FDA-approved  
 pharmaceuticals such as atovaquone and azithromycin (these are assumed to suppress the growth of Babesia parasites).3                          
 Recent                                                                                                                                         
 market data shows that Tafenoquine appears to be increasingly prescribed by Lyme physicians to manage Chronic Babesiosis. This trend           
 may follow the recent publication of several case reports demonstrating activity in immunosuppressed patients with acute babesiosis,           
 and animal data showing eradication of Babesia parasites, Tafenoquine (primarily as Arakoda).4 The Company believes                            
 the recent increases in sales of Arakoda have been driven by organic growth of these activities. There are no formal epidemiological           
 publications articulating the incidence or prevalence of Chronic Babesiosis, so these metrics must be inferred based on data for PTLDS         
 and the rate of coinfection with Babesia parasites. Thus, the cumulative case load of Chronic Babesiosis may be as high as1.01                 
 million patients in the United States.5 We believe, based on our market research that at least 37% of this market, or 375,000                  
 cases, may be addressable with Tafenoquine during the remainder of its market exclusivity window for malaria. We are undertaking additional    
 research to determine how much additional market capture might be feasible.                                                                    
 Acute                                                                                                                                          
 infection with many different organisms (e.g. Borrelia, SARS-Cov-2, Epstein Barr virus) trigger “Long Syndromes” in a minority                 
 of cases, characterized by cognitive dysfunction, fatigue and post-exertional malaise.6 For many years, such conditions have                   
 been confusing to the mainstream medical community because there may not be formal diagnostic criteria or an established theory of disease.    
 This is changing with the advent of Long COVID, and a recent prominent paper outlined the pathophysiological mechanisms for the first          
 time.7 Although there is not yet supporting evidence in the medical literature, some key opinion